ALS (Amyotrophic Lateral Sclerosis) — Deal Benchmarks & Valuation
Market Analysis
ALS (Amyotrophic Lateral Sclerosis) is one of the most actively transacted indications in neurology licensing. Phase 2 deals for als (amyotrophic lateral sclerosis) carry a median total deal value of $3.9B, with upfront payments ranging from $214M to $659M. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for als (amyotrophic lateral sclerosis) licensing?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating